Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAPDH2)

• Drug Name: Cipaglucosidase alfa Drug Info
• Synonyms: Pombiliti

Indication

Disease Entry	ICD 11	Status	REF
Glycogen storage disease type II	5C51.3	Approved in EU	[1]
Pompe disease	5C51.3	Approved	[2]

• Cross-matching ID: TTD Drug ID: DMAPDH2

Molecule-Related Drug Atlas

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[4]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[5]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[6]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[7]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[8]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[8]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[8]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[9]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[9]
6-Deoxy-Alpha-D-Glucose	DM9HBY5	Discovery agent	N.A.	Investigative	[8]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[4]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[5]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[6]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[7]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[8]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[8]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[8]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[9]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[9]
6-Deoxy-Alpha-D-Glucose	DM9HBY5	Discovery agent	N.A.	Investigative	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Replacement	[3]

References

• [1] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [2] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [3] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [4] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [5] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [6] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [7] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [8] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [9] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.